- Home
- HNVR vs KZIA Comparison
HNVR vs KZIA Comparison
Compare HNVR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNVR | KZIA |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | Australia |
| Employees | N/A | 6 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 186.7M |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | HNVR | KZIA |
|---|---|---|
| Price | $27.26 | $11.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $24.50 | $19.50 |
| AVG Volume (30 Days) | 26.7K | ★ 255.7K |
| Earning Date | 04-27-2026 | 06-04-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $33.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $4.86 |
| 52 Week High | $27.89 | $17.40 |
Technical Indicators
Market Signals| Indicator | HNVR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 58.27 | 42.77 |
| Support Level | $26.41 | $11.39 |
| Resistance Level | $27.89 | $14.85 |
| Average True Range (ATR) | 0.61 | 1.11 |
| MACD | -0.08 | -0.26 |
| Stochastic Oscillator | 65.22 | 4.16 |
Price Performance
Historical ComparisonAbout HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.